The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
about
Pre-rheumatoid arthritis and its prevention.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial.EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohortCan rheumatoid arthritis be prevented?Rheumatoid arthritis in 2010: from the gut to the joint.Unresolved issues in biologic therapy for rheumatoid arthritis.The epidemiology of early inflammatory arthritis.Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis.Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review.Drug therapy in undifferentiated arthritis: a systematic literature review.When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Defining populations at risk of rheumatoid arthritis: the first steps to prevention.Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?Immunopathology alters Th17 cell glucocorticoid sensitivity.Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives.Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Guidelines for the drug treatment of rheumatoid arthritis.Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study.Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example.Editorial: Prevention of Rheumatoid Arthritis: Now Is the Time, but How to Proceed?The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities.Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
P2860
Q33806701-1E28173A-5773-46A1-B49C-FE5E0AF4F992Q35084199-E95697F2-D099-4CF5-A91F-690D51F82530Q35835735-6D182250-7765-439C-A474-C57C82BBE437Q35896648-0D030B56-0A3E-43CB-B1B4-4F6812542312Q36092234-8220144B-2744-4BF8-81E4-84B72E5CC00EQ36485495-5A2DECF7-1312-4184-86AC-FF77ABED1E1BQ37012698-FBCD5D63-3AD2-44FD-BFFA-4FB156437532Q37589108-CB53331D-E659-4E69-959D-45674E091EB3Q37834949-5AED1BB5-6652-45A5-B440-0966A01E00A1Q37851001-8CF85E0A-2241-4029-8257-7FBD1D642327Q37889117-49BD0857-7530-4303-805C-648442A53DDCQ37898025-F62A00B4-B35F-499B-9431-1B9AB199F537Q38024758-26A02BA3-7E49-4E2D-BB54-2447D08C95F0Q38099628-16F08E83-8707-4D2C-BDB9-3A128AC6880DQ38112676-5A71461D-7D12-4E74-AC96-BCD7A09FA15AQ38211695-BDE55D96-931B-46F5-B86D-1E8CB2CE1C37Q38220638-FEC89D28-E69B-4E0D-BB43-E744324CBA0EQ38259809-AF7DC83C-05AC-4A0F-8293-02DE56A00584Q38959155-D94161B5-A864-4282-8ECD-B4DDFD652C80Q38972344-2E008D9C-2169-4482-9A93-8E87AD78B0C7Q41948703-6572C9B9-5788-4496-8950-286C93B5597CQ43675571-DDE23853-9769-4BCF-94D2-D9E441315A9BQ45774455-56B5A1EF-5025-4460-BA32-61C2CC086B32Q50882942-3B830427-3FFF-48C7-B01B-BF7B294E6478Q50882987-AA962E12-8831-481D-A924-C36E397C4C40Q51068510-6B60F087-A5E1-428F-9B80-7D9EB7D6A991Q52887079-106324F0-4D1A-4C13-BF06-F4D147AC16D3Q53921002-92DFC4F4-5115-4FBB-A570-F4D27769A10FQ56334428-8FEC1DAD-2813-426C-A158-07A69C55F3D6
P2860
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en-gb
The Stop Arthritis Very Early ...... coids in very early arthritis.
@nl
type
label
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en-gb
The Stop Arthritis Very Early ...... coids in very early arthritis.
@nl
prefLabel
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en-gb
The Stop Arthritis Very Early ...... coids in very early arthritis.
@nl
P2093
P50
P356
P1476
The Stop Arthritis Very Early ...... coids in very early arthritis.
@en
P2093
Dimitri E Karateev
Désirée M van der Heijde
Ferdinand C Breedveld
Janitzia Vázquez-Mellado
Kerstin Brickmann
Kirsten N Verpoort
Tanja A Stamm
Thomas W J Huizinga
P304
P356
10.1136/ARD.2009.122473
P407
P577
2010-03-01T00:00:00Z
P6179
1015396346